ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ME 23andMe Holding Company

0.39
-0.022 (-5.34%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,111,171
Bid Price 0.36
Ask Price 0.44
News -
Day High 0.41

Low
0.35

52 Week Range

High
2.03

Day Low 0.39
Share Name Share Symbol Market Stock Type
23andMe Holding Company ME NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.022 -5.34% 0.39 23:00:02
Open Price Low Price High Price Close Price Previous Close
0.41 0.39 0.41 0.3964 0.412
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
5,610 3,111,171 US$ 0.400586 US$ 1,246,292 - 0.35 - 2.03
Last Trade Type Quantity Price Currency
18:59:23 5 US$ 0.386 USD

23andMe Holding Company Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
193.17M 482.92M - 219.64M -666.7M -1.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

23andMe News

Date Time Source News Article
6/10/202415:17Edgar (US Regulatory)Form 8-K - Current report
6/05/202406:00GlobeNewswire Inc.23andMe Launches New Genetic Report on Bipolar Disorder
6/04/202406:00GlobeNewswire Inc.23andMe and the Colorectal Cancer Alliance Collaborate to..
6/03/202407:06Edgar (US Regulatory)Form 8-K - Current report
6/03/202407:00GlobeNewswire Inc.23andMe Therapeutics Announces Positive Preliminary Phase 2..
5/29/202407:00GlobeNewswire Inc.Largest study on the LRRK2 variant leads to discoveries..
5/24/202415:06Edgar (US Regulatory)Form 8-K - Current report
5/23/202416:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/23/202415:07Edgar (US Regulatory)Form 8-K - Current report
5/23/202415:05GlobeNewswire Inc.23andMe Reports Fourth Quarter and Full Year Fiscal 2024..
5/21/202415:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/21/202415:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ME Message Board. Create One! See More Posts on ME Message Board See More Message Board Posts

Historical ME Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.38880.42590.3770.40812323,922,6670.00120.31%
1 Month0.5810.61610.3770.47681045,266,623-0.191-32.87%
3 Months0.44760.6380.350.48600195,574,556-0.0576-12.87%
6 Months0.891.020.350.61136956,394,628-0.50-56.18%
1 Year1.952.030.350.77955314,702,425-1.56-80.00%
3 Years11.0013.680.352.873,500,471-10.61-96.45%
5 Years11.0013.680.352.873,500,471-10.61-96.45%

23andMe Description

23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.

Your Recent History

Delayed Upgrade Clock